From the Food and Drug Administration.
Nightingale
S L
SL
D000280:Administration, Inhalation; D000329:Advertising / Q000592:standards*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000188:drug therapy; D017277:Drug Approval; D004345:Drug Industry / Q000592:standards*; D016568:Drugs, Generic / Q000592:standards; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology*; D007840:Latex / Q000009:adverse effects*; D013685:Telecommunications; D014031:Tobramycin / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D016568:Drugs, Generic; D007840:Latex; D014031:Tobramycin